Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [31] Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
    Biniakewitz, Matthew D.
    Kasler, Mary Kate
    Fessele, Kristen L.
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2021, 8 (01) : 18 - 24
  • [32] Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
    Suresh, Karthik
    Khinh Ranh Voong
    Shankar, Bairavi
    Forde, Patrick M.
    Ettinger, David S.
    Marrone, Kristen A.
    Kelly, Ronan J.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine L.
    Brahmer, Julie R.
    Feller-Kopman, David
    Lerner, Andrew D.
    Lee, Hans
    Yarmus, Lonny
    D'Alessio, Franco
    Hales, Russell K.
    Lin, Cheng Ting
    Psoter, Kevin J.
    Danoff, Sonye K.
    Naidoo, Jarushka
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1930 - 1939
  • [33] Immune Checkpoint Inhibitors in Older Adults
    Elias, Rawad
    Morales, Joshua
    Rehman, Yasser
    Khurshid, Humera
    CURRENT ONCOLOGY REPORTS, 2016, 18 (08)
  • [34] Immune Checkpoint Inhibitors in Older Adults
    Rawad Elias
    Joshua Morales
    Yasser Rehman
    Humera Khurshid
    Current Oncology Reports, 2016, 18
  • [35] Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma
    Rai, Pragya
    Shen, Chan
    Kolodney, Joanna
    Kelly, Kimberly M.
    Scott, Virginia G.
    Sambamoorthi, Usha
    IMMUNOTHERAPY, 2021, 13 (02) : 103 - 112
  • [36] Immunotherapy of cancer in the era of checkpoint inhibitor
    Mehmi, Inderjit
    Hamid, Omid
    CLINICAL & EXPERIMENTAL METASTASIS, 2022, 39 (01) : 231 - 237
  • [37] Immunotherapy of cancer in the era of checkpoint inhibitor
    Inderjit Mehmi
    Omid Hamid
    Clinical & Experimental Metastasis, 2022, 39 : 231 - 237
  • [38] Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors
    Welaya, Karim
    Loh, Kah Poh
    Messing, Susan
    Szuba, Emily
    Magnuson, Allison
    Mohile, Supriya Gupta
    Maggiore, Ronald John
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (03) : 523 - 528
  • [39] The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
    Mpakali, Anastasia
    Stratikos, Efstratios
    CANCERS, 2021, 13 (01) : 1 - 30
  • [40] Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
    Tan, Peixin
    Huang, Wei
    He, Xinyan
    Lv, Fengquan
    Cui, Yanhai
    Du, Shasha
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (02) : 64 - 73